I think it highly likely that the infusion arm, under previous management, was neglected for some time. Viewed as the red headed step child in the shadows of adapt and immunotherapies side.
Which is funny, because it's a concrete business that was bringing in solid returns.
It remains to be seen if it continues a solid growth trajectory. I've always advocated for the infusion business. Don't care where the money comes from as long as it comes.
I think it highly likely that the infusion arm, under previous...
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
0.000(0.00%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.30 | $19.00 | $18.00 | $363.4K | 19.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 500 | $18.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 1000 | 1 |
View Market Depth
| Last trade - 15.59pm 01/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |